ABSTRACT
In the search of tumor-inhibiting coordination compounds with improved clinical effectiveness, reduced toxicity and broader spectrum of activity, ruthenium– Dimethyl sulfoxide (DMSO) complexes are found of growing significance. This chapter deals with the development of novel ruthenium–DMSO-based drugs. Due to larger list of metallo-drugs, this is limited only to ruthenium–DMSO complexes with greater emphasis on their DNA binding, nuclease activity, bioactivities and their mode of actions. There is an enormous rise in the number of cancer patients, which constantly demands more efficient and potent anticancer agent for clinical purpose. To meet the demand, a variety of ruthenium complexes have been developed in the laboratory of chemists and they have of course shown activity against wider range of cancers, but most of them caused serious side effects. The study of DNA interaction with ruthenium–DMSO complexes and ruthenium-mediated DNA damage are important area of chemical research because of their therapeutic and anticancer research interest.
